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Abstract 
Background: The first-generation integrase inhibitors (INIs) raltegravir (RAL) and elvitegravir (EVG) have shown 
efficacy against HIV infection, but they have the limitations of once-more daily dosing and extensive cross-resistance. 
Dolutegravir (DTG, S/GSK1349572), a second-generation drug that overcomes such shortcomings, is under spotlight. 
The purpose of this study is to review the evidence for DTG use in clinical settings, including its efficacy and safety.
Methods: PubMed, EMbase, Ovid, Web of Science, Science Direct, and related websites were screened from estab-
lishment until July 2013, and scientific meeting proceedings were manually searched. Two reviewers independently 
screened 118 citations repeatedly to identify randomized controlled trials comparing the efficacy and safety of 
DTG-based regimen with those of RAL- or elvitegravir-based regimens. Using the selected studies with comparable 
outcome measures and indications, we performed a meta-analysis based on modified intention-to-treat (mITT), on-
treatment (OT), and as-treated (AT) virological outcome data. Independent data extraction and quality assessment 
were conducted.
Results: Four unique studies were included with the use of DTG in antiretroviral therapy-naive patients. In therapy-
naive patients, DTG combined with abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) resulted 
in a significantly better virological outcome with a mITT relative risk (RR)of 1.07 (95 % confidence interval (95 % CI 
1.03–1.12). Evidence further supported use of DTG had a better virological suppression in the 50 mg once daily group 
(mITT RR 1.07; 95 % CI 1.03–1.12) as well as in the sub-analysis in dolutegravir/efavirenz(DTG/EFV) and dolutegravir/
raltegravir (DTG/RAL) groups (RR 1.09, 95 % CI 1.03–1.15; RR 1.06, 95 % CI 0.98–1.15, respectively). In the matter of 
safety of DTG-based regimen, the risk of any event was RR 0.98 (95 % CI 0.94–1.01), the risk of serious adverse events 
(AEs) was RR 0.84 (95 % CI 0.62–1.15), and the risk of drug-related serious AEs was RR 0.33 (95 % CI 0.13–0.79).
Conclusion: In general, DTG 50 mg given once daily combined with an active background drug is a better choice in 
terms of both efficacy and safety.
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Background
Since acquired immune deficiency syndrome (AIDS) 
was first identified as a serious communicable disease 
in 1981, an estimated 35.3 (32.2–38.8) million people 
were living with HIV in 2012 [1]. Stable integration of 
the reverse-transcribed viral genome into host chroma-
tin forms a significant mechanism during HIV infection. 
Integrase inhibitors (INIs) are a class of antiretroviral 
drugs targeting the strand transfer reaction during the 
integration process. It is active against HIV-1 strains that 
are resistant to nucleoside or nucleoside reverse tran-
scriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), and protease inhibi-
tors [2]. Unlike other enzymes that exist in viruses and 
humans, integrase enzymes are absent in mammalian 
cells. Therefore, blockade of integrase is highly specific 
to viruses and is associated with low toxicity [3]. The 
first-generation INIs raltegravir (RAL) and elvitegravir 
(EVG) have shown high efficacy against HIV in treat-
ment-naive and treatment-experienced individuals [4–
10]. Nevertheless, RAL must be taken twice daily, while 
EVG requires a pharmacokinetic booster such as rito-
navir or cobicistat [11–13]. Moreover, there is extensive 
cross-resistance between RAL and EVG [14]. Dolute-
gravir (DTG, S/GSK1349572), a new INI drug without 
such shortcomings, is under spotlight. It is an effective 
inhibitor of HIV integrase and HIV replication in cell 
culture assays even at low concentrations of nanomo-
lar level [11]. Pharmacokinetic studies in people have 
also shown DTG has a long plasma half-life without the 
need for a booster [15]. Furthermore, significant reduc-
tions in plasma HIV-1 viral load from baseline were 
observed for all DTG regimen groups compared with 
placebo (p < 0.001), with a mean decrease of 1.51–2.46 
log10 copies/mL [14]. Finally, results from in vitro pas-
sage experiments showed its potential for a higher bar-
rier to drug resistance compared with RAL and EVG 
[12]. The VIKING study has suggested that DTG is active 
against HIV-1 strains harbouring major integrase inhibi-
tor resistance mutations selected by both RAL and EVG 
[15–18]. Taken together, these studies show that DTG 
has low cross-resistance, with the potential for a higher 
barrier to resistance than other integrase inhibitors.
Combination therapy is the recognised care for HIV-
infected patients. Potential interaction between S/
GSK1349572 and other antiretroviral drugs has been 
evaluated in previous studies. Most antiretroviral and 
other drugs often prescribed for people with HIV infec-
tion do not have clinically relevant interaction with DTG, 
according to results of several studies [19]. To assess the 
efficacy and safety of DTG-based regimens, randomized 
controlled trials (RCTs) were designed to compare DTG-
based regimen with the currently approved combination 
therapy. Some studies found that a switch to a DTG-
based therapy was not superior to the approved combina-
tion therapy [20, 21]. However, in other studies, statistical 
superiority of a DTG-based therapy over the approved 
combination therapy was also reported [22, 23]. Thus, 
the results of these studies are still inconclusive. This 
issue sparks our interesting to pool samples from RCTs 
and to get an enlarged sample size, which can make the 
evaluation more reliable. In this study, a meta-analysis of 
current evidence was conducted to assess the safety and 




We followed a protocol using the methodologi-
cal approaches outlined in the Agency for Healthcare 
Research for Effectiveness and Comparative Effectiveness 
Reviews [24]. The systematic review included both pub-
lished studies and reports from scientific meeting pro-
ceedings. Two independent reviewers screened the titles 
and abstracts of eligible studies. The literature search was 
conducted in PubMed, EMbase, Ovid, Web of Science, 
Science Direct database from their establishments to July 
2013, and limited to English publications. The key words 
used were as follows: “HIV”; “dolutegravir”; “DTG”; “S/
GSK1349572”; or “integrase inhibitor”. At the same time, 
if we found any related documents, we went back to its 
references for further searching.
Study selection
Inclusion and exclusion criteria were as follows:
(1)   We included RCTs comparing DTG-based regi-
men with RAL- or elvitegravir-based regimens in 
efficacy and safety. and excluded studies on experi-
mental drugs, reviews, and technical papers.
(2)   Language restriction was set to English.
(3)   We included trials with the same or a similar study 
design, prior to those with the same randomized 
period. We excluded studies on pharmacokinet-
ics and dynamics. When the related studies by the 
same authors were found, we chose the study with 
the biggest sample size and most typical samples.
(4)   We included original research papers and abstracts 
of clinical trials on the use of DTG in HIV-positive 
patients and excluded in vitro and animal studies.
The study flow diagram is described in Fig. 1.
Data extraction and quality assessment
All selected articles or abstract-only reports were care-
fully read and analysed. We assessed the strength of 
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evidence by using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
approach [25]. The methodological quality of the 
included RCTs was assessed using the standard Jadad 
score [26] based on evaluation of randomization, blind-
ing, and follow-up, with a maximum score of 5 points. A 
score of 0–2 indicates low quality, while a score of 3–5 
indicates high quality. The Jadad scores of selected papres 
are shown in Table 1.
Data synthesis
The following data were collected: (a) basic study char-
acteristics including study phase, single centre or 
multicentre; (b) population characteristics including 
population size, sample characteristics, pre-trial antiret-
roviral treatment, and exclusion criteria; (c) intervention 
characteristics including the drugs used, drug dos-
age, duration of treatment, and follow-up; (d) outcome 
parameters including virological and immunological 
responses, clinical and laboratory adverse events (AEs); 
(e) to compare the efficacy of DTG (INI) versus EFV 
(NNRTI) and RAL (INI), we performed a sub-analysis on 
the virological outcome. Of all studies, we selected EFV 
or RAL as the control drug.
Data analysis
Two reviewers independently performed literature 
searching, evaluation of literature quality, informa-
tion extraction, and cross checking. In case of disagree-
ment, they discussed the issue until a consensus opinion 
was obtained. Statistical analyses were performed using 
STATA10.0 (American Computer Resource Center) 
and RevMan5.0 (The Cochrane Library), following the 
Mantel–Haenszel model to obtain weight-related risks 
(p < 0.05 for the χ2 statistic or a non one between-study 
variance by the DerSimonian and Laird [D + L] random-
effects model) and 95  % confidence intervals (CIs) of 























Records identified through 
database searching
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through other sources
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Full-text articles included in 
Meta-analysis of RCTs
(n=4)
Full-text articles included in 
Qualitative synthesis
(n=11)





Records excluded: cohort studies and 
case control studies (n=4)
Records excluded: studies on 
pharmacokinetics and dynamics (n=11) 
Records excluded: studies with 
experimental drug (n=55), reviews (n=17), 
Non-English (n=14)
Fig. 1 Literature search and study selection
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heterogeneity of treatment effects among trials within 
each meta-analysis, because meta-analyses with homog-
enous treatment effects among trials are unlikely to find 
that estimates of treatment effects are associated with 
quality measures (or other factors).
Sensitivity analysis
The primary results may be influenced by the use of 
fixed-effects models or random-effects models, as well 
as high-quality studies or low-quality studies. Sensitiv-
ity analysis was performed by excluding one low-quality 
study and one study with no statistical significance. Due 
to insufficient data, it is not always possible to carry out 
anticipated subgroup comparisons and sensitivity analy-
ses. We could not perform a planned subgroup com-
parison on different corticosteroid agents, because the 
included studies all used DTG.
Estimate of publication bias
Data were analysed using STATA 10.0 software. We cal-
culated the relative risk (RR) with 95 % CI. Statistical het-
erogeneity was quantified using the I2 statistic to measure 
the proportion of the overall variation, and strength of 
the evidence was assessed using the Chi squared test [29]. 
In pooling the data from included trials, a fixed-effects 
model was applied using the method of Mantel–Haenszel 
(M–H) when there was no statistically significant hetero-
geneity. A random-effects model was employed using the 
method of D + L if statistically significant heterogeneity 
was detected. Statistical significance of the test for het-
erogeneity was set at I2 = 50 % and p = 0.1. When we got 
different results, p > 0.1 or p < 0.1 was subject to our final 
confirmation. We could not perform a planned subgroup 
comparison because the included studies all used DTG,. 
A funnel plot was applied to examine potential publica-
tionbias in the meta-analysis. The fail-safe value was cal-






Selection process and study characteristics
The detailed search steps are summarised in the flow 
chart (Fig. 1). We initially identified 118 citations. After 
reading their titles and abstracts, we selected 17 poten-
tial articles for full-text view, including 11 articles of 
qualitative synthesis. After reading the texts, we excluded 
cohort studies, case control studies, uncontrolled trials, 
and studies with incomparable data. Finally, four articles 
[20–23] were related to clinical efficacy and safety RCTs 
of DTG, including one conference report [22].
All of the selected studies were 48 week duration, ran-
domized, double-blind, active-controlled, non-inferior-
ity, and multicentre trials with high scores on the Jadad 
scale (Table 1). All studies selected DTG-naive adults as 
research subjects. Of these studies, participants in two 
studies (50  %) were randomly assigned (1:1) to once-
daily DTG 50  mg group or twice-daily DTG 400  mg 
group, with investigator-selected background. Subjects in 
other two studies (50 %) studies [20, 22] were randomly 
assigned to receive once-daily DTG group or 600 mg efa-
virenz group. Three of the studies [20–22] selected an 
open-label dual NRTI backbone regimen with a fixed-
dose combination tablet, either abacavir/lamivudine 
(ABC/3TC) or tenofovir/emtricitabine (TDF/FTC). One 
studies [23] combined a variety of backbone regimens. 
These studies and the data used in the meta-analysis are 
listed in Table 2.
Meta-analysis
Subsequently, a meta-analysis of virological outcome 
(number of patients achieving HIV RNA <50 copies/mL) 
was performed on the four controlled studies that com-
pared a DTG-based regimen with EFV or RAL for similar 
indications, in which the same endpoints could be evalu-
ated (results available for the same measures and the 
same time points). Secondary endpoints analysed were 
the changes from baseline in CD4+ cell counts and the 
incidence of treatment-emergent genotypic and pheno-
typic resistance to DTG and other antiretroviral therapies 
used in the study [20–23].
The efficacy of DTG for all different subjects
The four studies [20–23] included in a total of 2575 HIV-
infected subjects, with 1334 experimental subjects (dose 
was not distinguished) and 1241 control subjects. Based 
on our pre-defined criteria for meta-analysis, DTG-based 
regimens showed a better virological outcome, which got 
a significant difference in the intention-to-treat (ITT) 
meta-analysis (RR 1.07, 95  % CI 1.03–1.12, p =  0.0003, 
I2 = 7 %; Fig. 2).
Median CD4+ cell counts increased compared to base-
line level in all studies, and DTG regimens had a higher 
level of CD4+ cell counts than traditional antiretroviral 
drugs (EFV or RAL) [20–23].
The efficacy of DTG 50 mg once daily
All of the studies [20–23] contained a 50 mg once-daily 
subgroup in the experimental group, so we selected 
this subgroup to analyse. There were 1022 subjects in 
the experimental group and 960 subjects in the control 
group. The results of the ITT meta-analysis were RR 1.07 
(95 % CI 1.03–1.12), p = 0.0003, I2 = 8 % (Fig. 2).
The efficacy of DTG 50 mg once daily vs. EFV and RAL
In these studies, 379 subjects received EFV in the control 
group and 410 subjects received DTG reversely [20, 22]. 
The Forest plots of the meta-analysis are shown in Fig. 2. 
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The results were statistically significant (RR 1.09, 95 % CI 
1.03–1.15, p = 0.002, I2 = 0 %).
There were 772 subjects who received RAL and 765 
subjects received DTG in the experimental group [21, 
23]. The Forest plots of the meta-analysis are shown in 
Fig. 2. The outcome of subjects who received RAL 400 mg 
twice daily was ITT RR, M-H, fixed (95 % CI) 1.06 (1.01–
1.12), Z = 2.23 (p = 0.02), I2 = 54 % (p = 0.14).
The safety of DTG for different subjects
Three of the selected studies [20–22] had a larger pro-
portion of participants, including 980 subjects in the 
Table 2 Overview of  studies in  systematic review, grouped according to  outcome data from  virology and  immunology 
response and serious drug- related AEs
DTG dolutegravir, S/GSK1349572; RAL raltegravir; EFV efavirenz
Authors and publish time Virology and immunologic response Serious drug- related AEs
Experiment group,  % (n/N) Control group, n (%) Experiment group, n (%) Control group, n (%)
Jan van Lunzen et al. 2012. [20] 10 mg: 91 % (48/53) 25 mg: 88 % 
(45/51) 50 mg: 90 % (46/5150)
EFV (600 mg): 82 % (41/50) 0 2 % (1/50)
Pedro Cahn et al. 2013. [23] 50 mg: 71 % (251/354,378) RAL (400 mg): 64 % (230/414) 1 % (2/378) 1 % (4/414)
Francois Raffi et al. 2013. [21] 50 mg: 88 % (361/411) RAL (400 mg): 85 % (351/411) <1 % (3/411) 1 % (5/411)
S. Walmsley et al. 2013. [22] 50 mg: 88 % (364/414) RAL (400 mg): 81 % (338/419) <1 % (1/414) 2 % (8/419)
Fig. 2 Forest plot of studies with patients switching with suppressed viral load
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experimental group and 880 subjects in the control 
group. An ITT analysis of the serious drug-related 
adverse reaction at 48  weeks comparing DTG versus 
atazanavir(ATV) showed an RR favouring DTG over 
efavirenz/raltegravir (EFV/RAL) in the meta-analysis 
(ITT, RR 0.33, 95  % CI 0.13–0.79, p =  0.25, I2 =  0  %; 
Fig.  3). Furthermore, when the DTG 50  mg once daily 
group and EFV/RAL group were analysed, the results 
were similar: RR 0.33, 95  % CI 0.13–0.79, p  =  0.25, 
I2 = 0 % (Fig. 3).
Serious drug‑related adverse reactions with DTG 50 mg 
once daily vs. EFV and RAL
In these studies, there were 432 subjects who received 
EFV in the control group and 536 subjects who received 
DTG reversely [20, 22]. The results included a study of 
comparing DTG with EFV (RR 0.12, 95 % CI 0.02–0.71, 
p = 0.02, I2 = 0 %). The Forest plots of the meta-analysis 
are shown in Fig. 3.
There were 773 subjects who received RAL and 768 
subjects who received DTG in the experimental group 
[21, 23]. Three studies compared DTG with RAL (RR 
0.56, 95 % CI 0.19–1.66, p = 0.29, I2 = 0 %). The Forest 
plots of the meta-analysis are shown in Fig. 3.
Sensitivity analysis
The primary results were not influenced by the use of 
fixed-effects models compared with random-effects 
models, or high-quality studies compared with low-qual-
ity studies.
Publication bias
The included studies appeared in the funnel plot com-
pletely and were distributed around the pooled RR, with 
large sample size at the top. We also performed fun-
nel chart linear regression analysis. The results on effi-
cacy showed that the intercept’s 95  % CI −5.144186 to 
8.272042, contained 0; p =  0.421  >  0.1, and the results 
Fig. 3 Forest plot of studies with patients switching with serious drug-related AEs
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of the 50 mg group showed that the intercept’s 95 % CI 
−4.91207 to 7.845071, containing 0, p = 0.427. This indi-
cated that the funnel plot was symmetrical. In addition, 
the results on safety showed that the 95 % CI −85.60035 
to 74.68191, containing 0, p = 0.546 > 0.1.
The fail-safe value of this study was 15.11 and 54.56, 
which means that it would take at least 15 and 54 unpub-
lished, especially negative results in the literature to over-
ride the conclusion of the meta-analysis.
Discussion
Dolutegravir (DTG, S/GSK1349572) works primarily 
by inhibiting the enzymatic activity of HIV-1 integrase, 
which catalyses the insertion of viral DNA into the chro-
mosomes of infected CD4+ lymphocytes [13, 31]. Sep-
arate trial comparing DTG-based therapy with other 
approved regimens could not confirm the advantages or 
disadvantages of DTG-based therapy. We performed a 
systematic review on all published clinical data concern-
ing the integrase inhibitor DTG and subsequently carried 
out a meta-analysis on the virological outcome of those 
studies. The endpoint of the trial was the proportion of 
participants in each treatment group that achieved a 
viral load lower than 50 copies/mL at week 48, which was 
established by the US Food and Drug Administration, to 
define the time to loss of virological response (TLOVR) 
algorithm. Based on the meta-analysis, treatment with 
DTG in combination with an active background drug 
showed superior virological control compared with 
RAL 400 mg or EFV 600 mg given twice daily, although 
the significance was marginal. Sensitivity analysis could 
not identify a study that changed the results. The funnel 
plot was also symmetrical. Sub-analysis of subjects given 
DTG 50 mg once daily showed that they were more likely 
to achieve virological control than subjects given DTG 
10 mg, 25 mg once daily. This result supported the strat-
egy of a phase 3 clinical study to select the dose of 50 mg 
once daily for the study [20]. The antiviral response 
of DTG may be related to the favourable CD4+ T cell 
responses [20], and DTG may have a higher barrier to 
drug resistance.
The sub-analysis comparing DTG given 50  mg once 
daily with EFV given 600  mg given once daily showed 
that better viral suppression of DTG combined with dual 
NRTIs over EFV-based first-line therapy, which is con-
sistent with a previous report showing that the increase 
of CD4+ T cells from baseline to week 48 was higher 
in DTG recipients than in EFV controls. Moreover, no 
resistance to DTG and NIRT therapy was described in 
the DTG group, whereas one case of NRIT and four cases 
of non-NRTI resistance mutation were found in EFV-
based first-line therapy [20, 22]. Furthermore, improve-
ments in viral suppression were statistically significant 
for DTG once-daily versus RAL twice-daily regimens in 
switch studies. The reason for this result appears not to 
be related to the marginal and nonsignificant increase 
in CD4+ T cells, however, is possible to be due to the 
treatment-emergent integrase mutation induced by RAL. 
Previous reports have noted that no treatment-emergent 
integrase mutations were detected in the DTG group. 
But 19 cases with integrase inhibitor-associated resist-
ance and 4 cases with NRTI mutations were detected [21, 
23]. Therefore, DTG in combination with other antiret-
roviral drugs (ARTs) has a higher virological efficacy and 
a higher barrier to resistance compared with RAL-based 
therapy and EFV-based regimens.
More attention should be paid to the safety of a new 
drug, as it is possible to decrease patient adherence to 
treatments by increasing drug toxicities. Serious drug-
related adverse events were chosen as our primary out-
come as a measure of the frequency of both clinically 
important and potentially life-threatening adverse drug 
events. A meta-analysis was performed on RCTs, com-
paring serious drug-related AEs (all grades) in DTG-
based regimens with those in EFV- or RAL-based 
regimens. We found that patients in DTG-based regi-
mens were twice less as likely to switch regimens due to 
any serious drug-related AEs compared with patients in 
EFV-based or RAL-based therapy. The most common 
AEs with DTG reported from the trials were nausea and 
headaches [20–23]. The forest plots for the clinical AEs 
suggest no statistically significant difference between 
DTG-based regimens and EFV- or RAL-based regi-
mens. Although I2 = 54 % >50 %, p = 0.14 > 0.1 shows 
that heterogeneity in this study is qualified for getting a 
conclusion from meta analysis, it should not be ignored, 
since there are still some clinical heterogeneity among 
the included studies. For example, the open-label dual 
NRTI backbone regimen with a fixed-dose combination 
tablet is different in some studies. In studies of Jan van 
Lunzen et al., Pedro Cahn et al., and Francois Raffi et al., 
the regimen is TDF/FTC or ABC/3TC, but in S. Walms-
ley’s study, it is ABC/3TC. [22]. There was no publication 
bias because we have removed the poor-quality litera-
ture. Subgroup analysis highlighted some differences in 
outcomes reported by different studies. Subjects receiv-
ing DTG 50 mg once daily were reported no significant 
increase in the frequency of serious drug-related AEs 
compared with subjects receiving EFV 600  mg twice 
daily or RAL 400 mg once daily. The results consistently 
support the strategy of a phase 3 clinical study to select 
the dose of 50 mg once daily for the study [20]. An addi-
tional sub-analysis was performed to compare serious 
drug-related AEs in the DTG 50 mg once daily regimen 
with EFV-based or RAL-based regimens. The forest plot 
shows fewer serious drug-related AEs in DTG treatment 
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compared with EFV-based first-line therapy. The seri-
ous drug-related AEs included hypersensitivity, psycho-
sis, cerebrovascular accidents, renal failure, and suicide 
attempts. However, there was a similar rate of serious 
drug-related AEs including aphasia, arrhythmia, con-
vulsion, diarrhoea, hepatitis, hypersensitivity, and phos-
phokinase (CPK) among DTG-based and RAL-based 
regimens, possibly due to the similar structure of these 
INIs.
Laboratory toxicity was estimated to assess the safety 
of DTG. Few subjects had an increase in alanine ami-
notransferase (ALT), about five or more times as the 
upper limit of normal, which was defined as grade 3–4 
laboratory toxicity [32]. However, most of them were 
infected with hepatitis virus. Only one case was con-
firmed to be a drug-induced liver injury related to DTG. 
Furthermore, a non-progressive increase in serum cre-
atinine was evident and remained stable to week 48. 
This result supports an in vitro study showing that DTG 
is a potent inhibitor of human organic cation transport 
(OCT)-2 at clinically relevant concentrations. Another 
study on healthy participants confirmed that DTG had 
no significant effect on glomerular filtration rate or effec-
tive renal plasma flow [33]. None of the patients receiving 
DTG discontinued the therapy because of renal toxicity. 
The SPRING-2 study reported no clinically significant 
changes over time in the fasting lipid profile in either 
the DTG or EFV group, while it noted that participants 
receiving DTG had more favourable changes in lipids 
than those in the EFV group [21]. With the similar phar-
macological mechanism with RAL, the result was sup-
ported by in  vitro experiments showing little effect of 
RAL on cellular adipogenesis and lipolysis [34]. Thus, 
DTG has the potential to improve adherence in HIV-
infected patients and increases the long-term tolerability 
of combination ART.
Our study has some limitations. On the demographic 
characteristics, the low proportion of non-white and 
female patients enrolled was not fully representative of 
the global HIV/AIDS epidemic. Moreover, the selected 
studies were not powered to rule out all potential differ-
ences in safety, so that we could not estimate the safety 
of DTG-based regimen in general. Other variables might 
explain the relationship between the changes in CD4+ 
cell counts from baseline and viral load. But they were 
not adequately reported by the studies, including the 
range of changes. The effects on viral outcome and AE 
frequency might also be different with longer follow-up 
periods. But the selected trials were ongoing and data 
at week 96 have not been reported so far. However, we 
reviewed the safety and efficacy of DTG-related regimens 
at week 48. The time point used to calculate the propor-
tion of patients with HIV-1 viral load less than 50 copies/
mL, was the primary endpoint. Although the literature 
included in this analysis were of high quality, the number 
of studies was still small, which might reduce the stability 
of the conclusions.
Taken together, in this study, we found that DTG in 
combination with up to two additional ARTs has higher 
virological suppression efficacy and a higher barrier to 
resistance compared with RAL- or EFV-based regimen. It 
is also an interesting agent with the potential to improve 
adherence in HIV-infected patients and increase the 
long-term tolerability of combination ART.
Conclusion
These results show that DTG 50  mg given once daily 
combined with an active background drug provides supe-
rior virological control and fewer adverse reactions com-
pared with raltegravir 400 mg or efavirenz 600 mg given 
twice daily.
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